AAAAAA

   
Results: 1-19 |
Results: 19
RANDOMIZED PLACEBO-CONTROLLED AND BALLOON-ANGIOPLASTY-CONTROLLED TRIAL TO ASSESS SAFETY OF CORONARY STENTING WITH USE OF PLATELET GLYCOPROTEIN-IIB IIIA BLOCKADE/
Authors: TOPOL EJ LINCOFF AM CALIFF RM TCHENG JE KLEIMAN NS ADELMAN AG BURTON JR TALLEY JD IVANHOE RJ DUCAS C CHEUNG PK SCHICK U BADARD D KRAMER J LEARY J SNYDER H WILSON R DEAREN M CARAMORI P WEBBER S TAYLOR J FERRANDO T COHEN E BALLEZA L ROUSE C HOGG N KELLY T ALSTON S WEBB J BULLER E RICCI DR MOCKMAN S TANGUAY JF POITRAS AM TIMIS G DAVEY D COLEMAN P HERROLDRUNGE P ONEILL BJ FOSHEY K FITZGERALD N ALMOND D KOSTUK W WHITE J OSKALNS R GOTTLIEB R KOREN P PALAZZO D AZRIN M BARRY MB BLANKENSHIP J DEMKO SL KRAFT P DVORAK L BROWN R COLCLOUGH M STEVENS K SAREMBOCK I SNYDER L SAYRE S BROWNE K ROY M REEN B SHORT R THOMPSON M CHIODO V HOFFMAN D BASS TA ZENNI M ROHMAN G MARQUIS JF LABINAZ M JELLEY J FRENCH W GOLDBERG S WANG S GRADMAN A BOLTEY L COLLINS J WORLEY S HOLLYWOOD L FREY L YAKUBOV S GILLILAND C RODRIGUEZ A POTTER K TAYLOR M AJI J CLEARY E TANNENBAUM M HARTZ A RUND M SMIGLEY R LOPEZ J KUNNY P HOCHMAN J SLATER J TERMEY D BATES E FOXBRUENGER P GONZALEZ M JOPPERRI L RUNYON JP HIGBY N KRUCOFT M BOOTH T AGUIRRE F BACH R MECHEM C AZRIN M MURPHY D CUMMINS FE NONWEILER J SANZ M COLE C WESTON MW ANDERSON HV WEIGELT L LARKIN T JACKSON BJ ROSENBERG MJ TULLY S HARTMAN C LUNOW S LUCORE C MISHKEL G MCSHANE K MUHLESTEIN B JERMAN J SANDER G STEVENS A CHISHOLM R DELCORE M STENGEL L CANNATA R CASTLE V DELUCA S BALOG C KNUTH T MCCOLLOUGH T GODFREY N MELTON J MILLER D PULLIAM M SAPP S SIGMON KN TEMPLIN M MONTAGUE E CARLSON J HEIL L ZOVKIC V MALONE K RODKEY S HAAS G HARRINGTON R KAPADIS S CAMPBELL L MUKHERJEE D DEEDY M AUGOSTINI R ALEXANDER J WHELLAN D BAJZER C RABBANI R CLEMONS P BAISHNAB R RANDALL R UNDERWOOD D LAUER MA LAUER MS ROE M FARHY R SCHWEIKERT R GRADY T ELLIS S MOLITERNO D DEBOWEY D IVANC T OLS L POLISZCUK R BALAZS E WITHERSPOON B ANDERSON KM BARNATHAN E CABOT CF STONER GL WEISMAN HF
Citation: Ej. Topol et al., RANDOMIZED PLACEBO-CONTROLLED AND BALLOON-ANGIOPLASTY-CONTROLLED TRIAL TO ASSESS SAFETY OF CORONARY STENTING WITH USE OF PLATELET GLYCOPROTEIN-IIB IIIA BLOCKADE/, Lancet, 352(9122), 1998, pp. 87-92
THE EPISTENT TRIAL AT 6 MONTHS - RELATIVE AND COMBINED EFFECTS OF ABCIXIMAB AND STENTING ON REDUCTION OF ACUTE ISCHEMIC EVENTS AND LATE REVASCULARIZATION
Authors: LINCOFF AM TCHENG JE CALIFF RM CABOT CF BOOTH JE GODFREY NK TOPOL EJ
Citation: Am. Lincoff et al., THE EPISTENT TRIAL AT 6 MONTHS - RELATIVE AND COMBINED EFFECTS OF ABCIXIMAB AND STENTING ON REDUCTION OF ACUTE ISCHEMIC EVENTS AND LATE REVASCULARIZATION, Circulation, 98(17), 1998, pp. 4021-4021
6-MONTH ANGIOGRAPHIC OUTCOME WITH ABCIXIMAB AND STENTS - THE EPISTENTANGIOGRAPHIC SUBSTUDY
Authors: LINCOFF AM MOLITERNO DJ ELLIS SG DEBOWEY D CABOT CF BOOTH JE GODFREY NK TOPOL EJ
Citation: Am. Lincoff et al., 6-MONTH ANGIOGRAPHIC OUTCOME WITH ABCIXIMAB AND STENTS - THE EPISTENTANGIOGRAPHIC SUBSTUDY, Circulation, 98(17), 1998, pp. 4028-4028
ABCIXIMAB THERAPY AND UNPLANNED CORONARY STENT DEPLOYMENT - FAVORABLEEFFECTS ON STENT USE, CLINICAL OUTCOMES, AND BLEEDING COMPLICATIONS
Authors: KEREIAKES DJ LINCOFF AM MILLER DP TCHENG JE CABOT CF ANDERSON KM WEISMAN HF CALIFF RM TOPOL EJ
Citation: Dj. Kereiakes et al., ABCIXIMAB THERAPY AND UNPLANNED CORONARY STENT DEPLOYMENT - FAVORABLEEFFECTS ON STENT USE, CLINICAL OUTCOMES, AND BLEEDING COMPLICATIONS, Circulation, 97(9), 1998, pp. 857-864
ABCIXIMAB BENEFIT IN CORONARY INTERVENTION HAS NO GENDER BIAS - RESULTS OF EPIC, EPILOG AND CAPTURE TRIALS
Authors: KEREIAKES DJ LINCOFF AM SIMOONS ML DEBOER MJ TCHENG JE VAHANIAN A ANDERSON KM CABOT CF CALIFF RM
Citation: Dj. Kereiakes et al., ABCIXIMAB BENEFIT IN CORONARY INTERVENTION HAS NO GENDER BIAS - RESULTS OF EPIC, EPILOG AND CAPTURE TRIALS, The American journal of cardiology, 82, 1998, pp. 95-95
REDUCING THE RISK OF PERCUTANEOUS INTERVENTION AFTER CORONARY-BYPASS SURGERY - BENEFICIAL-EFFECTS OF ABCIXIMAB TREATMENT
Authors: TCHENG JE ANDERSON K TARDIFF BE CABOT CF LINCOFF AM CALIFF RM TOPOL EJ
Citation: Je. Tcheng et al., REDUCING THE RISK OF PERCUTANEOUS INTERVENTION AFTER CORONARY-BYPASS SURGERY - BENEFICIAL-EFFECTS OF ABCIXIMAB TREATMENT, Journal of the American College of Cardiology, 29(2), 1997, pp. 7395-7395
ABCIXIMAB (C7E3 FAB, REOPRO) WITH REDUCED HEPARIN DOSING DURING CORONARY INTERVENTION - FINAL RESULTS OF THE EPILOG TRIAL
Authors: LINCOFF AM TCHENG JE CALIFF RM CABOT CF MILLER DP BOOTH JE MONTAGUE EA ANDERSON KM TOPOL EJ
Citation: Am. Lincoff et al., ABCIXIMAB (C7E3 FAB, REOPRO) WITH REDUCED HEPARIN DOSING DURING CORONARY INTERVENTION - FINAL RESULTS OF THE EPILOG TRIAL, Journal of the American College of Cardiology, 29(2), 1997, pp. 7396-7396
BENEFITS OF ABCIXIMAB ACCRUE IN THE FULL SPECTRUM OF CORONARY INTERVENTIONAL PATIENTS - INSIGHTS FROM THE EPILOG TRIAL
Authors: TCHENG JE LINCOFF AM MILLER DP BOOTH JE RUND MM CABOT CF WEISMAN HF CALIFF RM TOPOL EJ
Citation: Je. Tcheng et al., BENEFITS OF ABCIXIMAB ACCRUE IN THE FULL SPECTRUM OF CORONARY INTERVENTIONAL PATIENTS - INSIGHTS FROM THE EPILOG TRIAL, Journal of the American College of Cardiology, 29(2), 1997, pp. 9931-9931
PLATELET GLYCOPROTEIN IIB IIIA RECEPTOR BLOCKADE AND LOW-DOSE HEPARINDURING PERCUTANEOUS CORONARY REVASCULARIZATION/
Authors: TOPOL EJ CALIFF RM LINCOFF AM TCHENG JE CABOT CF WEISMAN HF KEREIAKES D LAUSTEN D RUNYON JP HOWARD W KELLY T MUNCY D TIMMIS G SAFIAN M DAVEY D KLEIMAN NS ROSE D BASINGER L ROUSE C KRAMER J WILSON R TALLEY JD BOYLES M NAVETTA FI LEBUEUF R KRAFT P DVORAK L SMIGLA RM FERGUSON J HARLAN M BROWNE K TELATNIK M BLANKENSHIP J DEMKO L IVANHOE RJ JACKSON C SHADOFF N GOEBEL S TAYLOR M CLEARY E GACIOCH G CHIODO V BATES E QUAIN L SNYDER H BASS TA ROHMAN C GRADMAN A BOLTEY L TANNENBAUM M STENGL D GORDON P WRIGHT N CUMMINS F NONNWEILER J AVERSANO T PELTZER L BEAR P CRAIG MB HATTEL L TOOKE G ANDERSON HV WEIGELT L HETTLEMAN B KENNEDY S TEIRSTEIN PS CLAIRE D SAREMBOCK I SAYRE S DAVIDSON CJ SCHAECHTER A AGUIRRE F STONNER T AZRIN M BODETT J BARRY MB WORLEY S FREY LA SPRIGGS DJ WAHL SA WESTON MW YEDINAK K GEORGE B SMITH D GILLILAND C SMITH D RICCI DR FOX R HARTMAN C LUNOW S FARAH T PETRUOLO S SANDER G STEVENS A DELISE K REEN B WHISNANT D HENDERSON L HEUSER R SWIDERSKI K KALUZNIAK M LARKIN T JACKSON BJ POPMA J PRUNKA N SANZ M MAYER D MACKEY K BURTON J HOGG N BROWN R STEVENS K FRENCH W WANG S ADELMAN AG FOULGER V WEBER S GOTTLIEB R LAVOIE J KING S FRERICHS F HOLLYWOOD L DUCAS J SCHICK U HOCHMAN JS SLATER J TORMEY D ONEILL BJ FOSHAY K FITZGERALD N CHEUNG PK BEDARD D KNUDTSON ML GALBRAITH D WATT H SAMAHA J HAMILTON B KLEIN LW HEBSON L ALMOND D WHITE J ROSENBERG MJ TEULLY S UNKS M RODGERS K FAXON D GORE J KELSEY S LEE K SANE D WALTERS L BOOTH J CANNATA R CASTLE V COHEN H DELUCA S KUTNER M KNUTH T MCCOLLOUGH T MCPHERSON J MELTON J MILLER D PULLIAM M SAPP S SIGMON KN MONTAGUE E ALEXANDER K AUGOSTINI R BAJZER C BART B BELLI G CARLSON J CHALLAPALLI R CRENSHAW B DAWSON I DICKEY A ECHOLS A ERICKSON B FONTANA MB GHAFFARI S GORDON C GRANGER C GRANO G GRIMM R JOHNSON T JURAN N KINGSLEY A KRUSE K LAUER M MAHAFFEY K MALONE K MARK D MARWICK T MIGRINO R MILLER J NEWBY K PACE C PETERSON E RABBANI R RAGAN J RIMMERMAN C RODKEY S SAVOR V SHAW WF SILA C SILVER M TAN W TOBIASZ D VANDERVOORT P WANG CW WARD C WATERS J WIEHLE D WINCHELL M UNDERWOOD D CLEMONS P HEUPLER S POWERS J RUBIN D SGARBOSSA E STEINHUBL S MOLITERNO D DEBOWEY D BALAZS E CROWE T IVANC T OLS L POLISZCZUK R VILSACK H WITHERSPOON B DAVIDSONRAY L ANDERSON KM GIEL KM MUSCO MH STONER GL
Citation: Ej. Topol et al., PLATELET GLYCOPROTEIN IIB IIIA RECEPTOR BLOCKADE AND LOW-DOSE HEPARINDURING PERCUTANEOUS CORONARY REVASCULARIZATION/, The New England journal of medicine, 336(24), 1997, pp. 1689-1696
DECREASED VASCULAR ACCESS SITE BLEEDING AFTER CORONARY INTERVENTION WITH ABCIXIMAB IN THE EPILOG VS THE EPIC TRIAL
Authors: BLANKENSHIP JC ANDERSON KM DEMKO L CABOT CF KEREIAKES DJ AGUIRRE FV
Citation: Jc. Blankenship et al., DECREASED VASCULAR ACCESS SITE BLEEDING AFTER CORONARY INTERVENTION WITH ABCIXIMAB IN THE EPILOG VS THE EPIC TRIAL, Circulation, 96(8), 1997, pp. 896-896
DURABLE INHIBITION OF ISCHEMIC COMPLICATIONS BY ABCIXIMAB DURING PERCUTANEOUS CORONARY REVASCULARIZATION - ONE-YEAR RESULTS OF THE EPILOG TRIAL
Authors: LINCOFF AM TCHENG JE ANDERSON KM CABOT CF
Citation: Am. Lincoff et al., DURABLE INHIBITION OF ISCHEMIC COMPLICATIONS BY ABCIXIMAB DURING PERCUTANEOUS CORONARY REVASCULARIZATION - ONE-YEAR RESULTS OF THE EPILOG TRIAL, Circulation, 96(8), 1997, pp. 902-902
LONG-TERM MORTALITY BENEFIT WITH ABCIXIMAB IN PATIENTS UNDERGOING PERCUNTANTEOUS CORONARY INTERVENTION (PCI)
Authors: ANDERSON KM FERGUSON JI STONER GL CABOT CF WEISMAN HF
Citation: Km. Anderson et al., LONG-TERM MORTALITY BENEFIT WITH ABCIXIMAB IN PATIENTS UNDERGOING PERCUNTANTEOUS CORONARY INTERVENTION (PCI), Circulation, 96(8), 1997, pp. 903-903
IN-LAB ANGIOGRAPHIC COMPLICATIONS DURING CORONARY INTERVENTION WITH ABCIXIMAB VS PLACEBO IN THE EPILOG TRIAL
Authors: BLANKENSHIP JC ANDERSON KM DEMKO SL LINCOFF AM TCHENG JE CABOT CF
Citation: Jc. Blankenship et al., IN-LAB ANGIOGRAPHIC COMPLICATIONS DURING CORONARY INTERVENTION WITH ABCIXIMAB VS PLACEBO IN THE EPILOG TRIAL, Circulation, 96(8), 1997, pp. 905-905
REDUCED NEED FOR CORONARY-BYPASS SURGERY (CABG) AFTER PERCUTANEOUS INTERVENTION IN PATIENTS TREATED WITH ABCIXIMAB
Authors: TARDIFF BE ANDERSON KM CABOT CF DECKERS JW SIMOONS ML
Citation: Be. Tardiff et al., REDUCED NEED FOR CORONARY-BYPASS SURGERY (CABG) AFTER PERCUTANEOUS INTERVENTION IN PATIENTS TREATED WITH ABCIXIMAB, Circulation, 96(8), 1997, pp. 931-931
SHOULD DIABETICS TREATED WITH ABCIXIMAB RECEIVE MORE HEPARIN THAN NON-DIABETICS - FINDINGS OF A MULTICENTER TRIAL
Authors: KLEIMAN NS LINCOFF AM AGUIRRE FV KEREIAKES DJ MILLER DP CABOT CF ANDERSEN K TOPOL EJ
Citation: Ns. Kleiman et al., SHOULD DIABETICS TREATED WITH ABCIXIMAB RECEIVE MORE HEPARIN THAN NON-DIABETICS - FINDINGS OF A MULTICENTER TRIAL, Circulation, 96(8), 1997, pp. 2162-2162
STANDARD VERSUS LOW-DOSE WEIGHT-ADJUSTED HEPARIN IN PATIENTS TREATED WITH THE PLATELET GLYCOPROTEIN IIB IIIA RECEPTOR ANTIBODY FRAGMENT ABCIXIMAB (C7E3 FAB) DURING PERCUTANEOUS CORONARY REVASCULARIZATION/
Authors: LINCOFF AM TCHENG JE CALIFF RM BASS T POPMA JJ TEIRSTEIN PS KLEIMAN NS HATTEL LJ ANDERSON HV FERGUSON JJ CABOT CF ANDERSON KM BERDAN LG MUSCO MH WEISMAN HF TOPOL EJ
Citation: Am. Lincoff et al., STANDARD VERSUS LOW-DOSE WEIGHT-ADJUSTED HEPARIN IN PATIENTS TREATED WITH THE PLATELET GLYCOPROTEIN IIB IIIA RECEPTOR ANTIBODY FRAGMENT ABCIXIMAB (C7E3 FAB) DURING PERCUTANEOUS CORONARY REVASCULARIZATION/, The American journal of cardiology, 79(3), 1997, pp. 286-291
ANTIPLATETLET MONOCLONAL-ANTIBODIES FOR THE PREVENTION OF ARTERIAL THROMBOSIS - EXPERIENCE WITH REOPRO, A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GPIIB IIIA RECEPTOR/
Authors: WEISMAN HF SCHAIBLE TF JORDAN RE CABOT CF ANDERSON KM
Citation: Hf. Weisman et al., ANTIPLATETLET MONOCLONAL-ANTIBODIES FOR THE PREVENTION OF ARTERIAL THROMBOSIS - EXPERIENCE WITH REOPRO, A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GPIIB IIIA RECEPTOR/, Biochemical Society transactions, 23(4), 1995, pp. 1051-1057
COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGEDANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
Authors: ALTMAN R CARRERAS L DIAZ R FIGUEROA E PAOLASSO E PARODI JC CADE JF DONNAN G EADIE MJ GAVAGHAN TP OSULLIVAN EF PARKIN D RENNY JTG SILAGY C VINAZZER H ZEKERT F ADRIAENSEN H BERTRANDHARDY JM BRAN M DAVID JL DRICOT J LAVENNEPARDONGE E LIMET R LOWENTHAL A MORIAU M SCHAPIRA S SMETS P SYMOENS J VERHAEGHE R VERSTRAETE M ATALLAH A BARNETT H BATISTA R BLAKELY J CAIRNS JA COTE R CROUCH J EVANS G FINDLAY JM GENT M LANGLOIS Y LECLERC J NORRIS J PINEO GF POWERS PJ ROBERTS R SCHWARTZ L SICURELLA J TAYLOR W THEROUX P TURPIE AG WEISEL RD CUI J LIU L PIRK J BAY C BOYSEN G KNUDSEN JB PETERSEN P SORENSEN PS TONNESEN HK HARJOLA PT ARCAN JC BALKAU B BLANCHARD J BOISSEL JP BONEU B BOUSSER MG BROCHIER M CLOAREC M CRIBIER G DECHAVANNE M DROUIN P ESCHWEGE E GUIRAUDCHAUMEIL B HUGONOT R LEIZOROVICZ A LORIA Y MICHAT L MIROUZE J PANAK E PASTEYER J RASCOL A REVOL L ROY M SELLES J SLAMA G STARKMAN C TEULE M THIBULT N VERRY M ALBERT FW ANDRASSY K BREDDIN K ECKEL R ENCKE A FROHLICH J HARTUNG B HEISS HW HESS H HOFLING B KRAUSE D LATTA G LINKE H LOEW D LORENZ R MIDDLETON K NOVAK G OLDENDORF M PFLUGER N RAITHEL D REUTER R SCHETTLER G SCHNITKER J SCHOOP W STIEGLER H UBERLA K VOGEL G WEBER M WELBERS I ZEITLER E ARAPAKIS G CHAN T MOK CK SZABO R MISRA NP REDDY K FITZGERALD GA APOLLONIO A BALSANO F BASELLINI A CANDELISE L CATALANO M CIAVARELLA N CIUFFETTI G COCCHERI S CORTELLARO M CORVI G COTO V DAVI G DECATERINA R DIPERRI T FIESCHI C GENTILE R GREGORATTI L GRESELE P LAVEZZARI M LIBRETTI A MAGNANI B NENCI G PAGANO G PATRONO C PEDRINI L PINI M PRANDONI P ROMEO F ROVELLI F RUDELLI G RUVOLO G SIGNORINI GP TOGNONI G VIOLI F FUJIMORI T KAGEYAMA M KATSUMURA T KITAMURA S MAEDA K SUZUKI A TOHGI H UCHIYAMA S UTSUMI H GARCIA AM ALGRA A DENOTTOLANDER GJH KUPPER AJF VANGIJN J HART H KAPPELLE LJ KOUDSTAAL PJ LEMMENS T LODDER J PANNEBAKKER M SERRUYS PW VANDENBELT A VANDERMEER J VANDERVIJGH AB VERHEUGT FWA VETH G DALE J JOHANNESSEN KA THAULOW E POPESCU P TIBERIU N AZNAR JRD ESMATJES E GUITERAS P LASIERRA J LOPEZTRIGO P ORIOL A POMAR L ROCHA E SANCHEZ FD SANCHORIEGER J SANZ G BERGLUND ULF BLOMSTRAND C BOBERG M BRITTON M ELWIN CE HELMERS C HOLM J JANZON L JUULMOLLER S MULEC H OLSSON JE PERSSON S RASMANIS G ROSEN A SAMUELSSON K SOREFF J WAHLGREN N WALLENTIN L BAUR HR BOKSLAG M BOLLINGER A MEIER B PFISTERER M PFLUGER N SITTHIAMORN C ACHESON EJ APPLEBY P ASSCHER AW AUKLAND A BAIGENT C BALA S BARNETT AH BELL P BEWS S BORN GVR BRANAGAN JP BROOKS N BROWN MJ BROWSE NL CAPILDEO R CARMALT M CARTER AE CHALMERS I CLARKE M CLARKE RJ CLYNE CAC COLLINS R COOKE ED COUTTS G COVE DH CROWTHER PS CUTHBERTSON WF DEBONO D DICKERSON C DICKINSON JP DOLL R DORMANDY JA DUNBABIN D ELL S ELPHINSTONE P ELWOOD P ENGLISHBY V FARRELL B FISKERSTRAND C FLATHER M FOLEY T FOULDS T FOX KM FRANKS P FRASER H GARDECKI T GAWEL M GENT AE GERSHLICK AH GODWIN J GOLDMAN M GRAY C GRAY D GRAY R HANDOLL H HANKEY G HARRISON MJG HENDERSON N HEPTINSTALL S HOBBIGER SF JONES EW JONES NAG JOST S JULIAN D KELLETT J KESTER RC LOWE G MACKENZIE J MCCOLLUM CN MEAD G MEADE TW MENDELOW D MILLER JC MORRIS GK NICHOL C NOBLE M OBRIEN JR OGIER M PARISH S PARRY MJ PETO R POWELL J POZZILLI P QIZILBASH N RAHMAN A RAJAH SM RICHARDS DH RICHARDS S RIPLEY R ROBERTS VC ROSE FC RUSSELL RWR RUBIN PC RUCKLEY CV SANDERCOCK P SHAW MDM SHAW KM SHELLEY JH SLATTERY J SLEIGHT P SMITH SJ STEWARTLONG P SWEETNAM PM TANSEY MJB TINDALL H TURNEY J TYLER HM VAREY NC VESSEY MP WALKER MG WALKER MA WARLOW CP WILCOX RG WILLEMS H WOOD EH WYNJONES E ADAMS HP BARTON B BEDFORD RF BICK BL BINGHAM S BROWN BG BRYANT T BURING J CABOT CF CANNER P CHESEBRO J CHRISMAN OD CLAGETT GP COLWELL JA DYKEN M ELLIS D FIELDS WS FURBERG C FUSTER V GOLDMAN S GRANETT J GREEN RM GREEN D HARDY R HARKER LA HARRIS WH HART RG HASS WK HENNEKENS C HILL D HUME M IGLOE MC JOHNSON G JONAS S KNATTERUD G KOHLER TR LEMBO NJ LEWIS D LOCKHART E MAJERUS P MCENANY MT MCKENNA R MEHTA JL MEYER JS MOLONY B MORITZ T NICOLOFF DM NYCZ G ONO H PANTELY GA PHILLIPS SJ RIDKER P ROBERTSON JT ROTHBART R SALZMAN EW SAUTTER RD SCHLANT RC SCHOENBERGER JA SENGEKONTACKET MV SHARMA G STEELE P STEINNAGEL KP STRATTON J SULLIVAN JM TIMMIS G TOOLE JF WALKER MD WEISMAN S WHITE CW WIRECKI M WOMBOLT D WONG R YUSUF S ZADINA K ZUCKER D
Citation: R. Altman et al., COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGEDANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS, BMJ. British medical journal, 308(6921), 1994, pp. 81-100
RECOMBINANT HIRUDIN IN PATIENTS WITH CHRONIC, STABLE CORONARY-ARTERY DISEASE - SAFETY, HALF-LIFE, AND EFFECT ON COAGULATION PARAMETERS
Authors: ZOLDHELYI P WEBSTER MWI FUSTER V GRILL DE GASPAR D EDWARDS SJ CABOT CF CHESEBRO JH
Citation: P. Zoldhelyi et al., RECOMBINANT HIRUDIN IN PATIENTS WITH CHRONIC, STABLE CORONARY-ARTERY DISEASE - SAFETY, HALF-LIFE, AND EFFECT ON COAGULATION PARAMETERS, Circulation, 88(5), 1993, pp. 2015-2022
Risultati: 1-19 |